This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Aceragen Résultats passés
Passé contrôle des critères 0/6
Aceragen has been growing earnings at an average annual rate of 28.9%, while the Biotechs industry saw earnings growing at 23.7% annually. Revenues have been growing at an average rate of 34.1% per year.
Informations clés
28.9%
Taux de croissance des bénéfices
40.3%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 34.1% |
Rendement des fonds propres | -71.6% |
Marge nette | -559.9% |
Dernière mise à jour des bénéfices | 31 Mar 2023 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Ventilation des recettes et des dépenses
Comment Aceragen gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Mar 23 | 7 | -41 | 15 | 0 |
31 Dec 22 | 5 | -23 | 12 | 0 |
30 Sep 22 | 0 | -16 | 9 | 16 |
30 Jun 22 | 0 | -18 | 9 | 10 |
31 Mar 22 | 0 | -20 | 9 | -7 |
31 Dec 21 | 0 | 97 | 10 | 0 |
30 Sep 21 | 0 | 24 | 11 | 5 |
30 Jun 21 | 0 | 9 | 11 | 25 |
31 Mar 21 | 0 | -8 | 11 | 29 |
31 Dec 20 | 0 | -113 | 12 | 25 |
30 Sep 20 | 0 | -87 | 12 | 22 |
30 Jun 20 | 0 | -78 | 13 | 9 |
31 Mar 20 | 1 | -65 | 13 | 9 |
31 Dec 19 | 1 | -85 | 12 | 35 |
30 Sep 19 | 2 | -45 | 13 | 10 |
30 Jun 19 | 2 | -46 | 14 | 5 |
31 Mar 19 | 0 | -51 | 15 | 13 |
31 Dec 18 | 1 | -60 | 15 | 42 |
30 Sep 18 | 1 | -63 | 16 | 19 |
30 Jun 18 | 1 | -66 | 15 | 24 |
31 Mar 18 | 1 | -71 | 15 | 25 |
31 Dec 17 | 1 | -66 | 16 | 26 |
30 Sep 17 | 16 | -50 | 15 | 26 |
30 Jun 17 | 16 | -49 | 15 | 25 |
31 Mar 17 | 16 | -41 | 15 | 25 |
31 Dec 16 | 16 | -38 | 15 | 24 |
30 Sep 16 | 1 | -51 | 15 | 22 |
30 Jun 16 | 1 | -50 | 15 | 21 |
31 Mar 16 | 1 | -49 | 15 | 22 |
31 Dec 15 | 0 | -49 | 15 | 20 |
30 Sep 15 | 0 | -49 | 15 | 19 |
30 Jun 15 | 0 | -47 | 14 | 20 |
31 Mar 15 | 0 | -42 | 13 | 17 |
31 Dec 14 | 0 | -39 | 11 | 16 |
30 Sep 14 | 0 | -34 | 10 | 14 |
30 Jun 14 | 0 | -29 | 9 | 11 |
31 Mar 14 | 0 | -26 | 8 | 9 |
31 Dec 13 | 0 | -21 | 8 | 7 |
30 Sep 13 | 0 | -21 | 7 | 7 |
30 Jun 13 | 0 | -21 | 6 | 8 |
31 Mar 13 | 0 | -19 | 6 | 9 |
31 Dec 12 | 0 | -22 | 6 | 13 |
30 Sep 12 | 0 | -26 | 7 | 12 |
Des revenus de qualité: ACGN is currently unprofitable.
Augmentation de la marge bénéficiaire: ACGN is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ACGN is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.
Accélération de la croissance: Unable to compare ACGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ACGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Rendement des fonds propres
ROE élevé: ACGN has a negative Return on Equity (-71.58%), as it is currently unprofitable.